Seattle, United States
Ozette, founded in 2021 and based in the United States, is pioneering advancements in the field of single-cell analysis with its proprietary, computationally-driven analytics platform. Specifically designed for cytometry data, Ozette's platform automates complex analytical workflows, from raw FCS files to actionable insights, enabling scientists to prioritize discovery over data management.
The company's unique proposition lies in its partnership with leading immunologists and data scientists, ensuring unmatched accuracy and speed in immune monitoring and translational research. By harnessing the power of AI and Machine Learning, Ozette aids biotech and pharma teams in extracting profound biological meanings from every experiment, thereby accelerating clinical programs.
Ozette secured a $26.00M Series A investment on 01 July 2022 from investors such as Madrona, M12, and Alexandria Venture Investments, positioning itself as a vital player in the Biotechnology and Life Sciences industries. The investment underscores confidence in the company's capability to revolutionize single-cell data analytics.
